SULSTER Drug Patent Profile
Which patents cover Sulster, and when can generic versions of Sulster launch?
Sulster is a drug marketed by Epic Pharma Llc and is included in one NDA.
The generic ingredient in SULSTER is prednisolone sodium phosphate; sulfacetamide sodium. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate; sulfacetamide sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SULSTER?
- What are the global sales for SULSTER?
- What is Average Wholesale Price for SULSTER?
Summary for SULSTER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 4,711 |
| DailyMed Link: | SULSTER at DailyMed |
US Patents and Regulatory Information for SULSTER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epic Pharma Llc | SULSTER | prednisolone sodium phosphate; sulfacetamide sodium | SOLUTION/DROPS;OPHTHALMIC | 074511-001 | Jul 30, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
